by Kole Krieger | Oct 18, 2023 | News
Preventive drugs may be the best solution to the antibiotic resistance crisis By Brian Finrow Oct. 18, 2023 The antibiotics crisis is a silent pandemic that threatens to knock modern society back into the medieval age of therapeutic leaches and serum therapy. A world...
by admin | Apr 18, 2022 | News
By Jake Siegel and Brian Finrow Today we announced several milestones in the clinical development of LMN-201, Lumen’s orally delivered biologic cocktail to prevent C. difficile infection (CDI). The big headline: the FDA has greenlit Phase 2 studies of LMN-201. Soon we...
by admin | Mar 19, 2022 | News
Watch Webinar Here
by admin | Feb 1, 2022 | News
By Jake Siegel and Brian Finrow Last week we announced a new collaboration with Aridis Pharmaceuticals to develop an intranasal passive vaccine to fight flu. We have written before about our efforts to use our unique manufacturing platform to develop edible antibody...
by admin | Dec 24, 2021 | News
By Brian Finrow and Jim Roberts We just released a paper on the preclinical development of LMN-201, Lumen’s orally delivered cocktail of therapeutic proteins for preventing C. difficile infection. In the news release we also shared that LMN-201 met its primary...
Cognition Live Article on RePreve Trial
LMN-201 Achieves 100% Initial C. difficile Clinical Cure in Preliminary Cohort of RePreve Trial
Preventive antimicrobials: A promising solution to antibiotic resistance
Preventive Biologics May Aid the Antibiotic Resistance Crisis
Q&A: Biologic drugs are reinvented to treat infectious diseases